Clinical trial · Observational
Retrospective Investigation of the Impacts of Prognosis for Nasopharyngeal Carcinoma Patients
Stage-specified Concurrent Chemoradiotherapy With or Without Induction Chemotherapy for Locoregionally-advanced Nasopharyngeal Carcinoma - A Retrospective, Population-based Study
NCT02604472CI-TRIAL-00019780completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To investigate whether the additional induction chemotherapy (IC) to concurrent chemoradiotherapy (CCRT) was able to improve overall survival (OS) and disease-free survival (DFS), and to clarify if stage-specified chemoradiotherapy regimens benefit the most for locoregionally advanced NPC.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Malignant Neoplasm of Other Specified Site of Nasopharynx | Nasopharyngeal Carcinoma | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| CCRT | Other | — | UNRESOLVED |
| IC+CCRT | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- CCRT group
- description
- Locoregionally advanced nasopharyngeal carcinoma patients received concurrent chemoradiotherapy
- interventionNames
- Other: CCRT
- label
- IC+CCRT group
- description
- Locoregionally advanced nasopharyngeal carcinoma patients received induction chemotherapy and concurrent chemoradiotherapy
- interventionNames
- Other: IC+CCRT
Primary outcomes (1)
- measure
- overall survival
- timeFrame
- up to 10 years
Secondary outcomes (1)
- measure
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: 1. firstly diagnosed NPC in SYSUCC from Jan 1st, 1998 to Jun 1st, 2013; 2. with complete medical records; 3. received radical RT. Exclusion Criteria: 1. distant metastasis patients at first diagnosis, 2. recurrent patients, 3. not finishing radiotherapy, missing medical data, death during RT, stage I or II disease,received treatment previously, or without concurrent chemoradiotherapy were excluded.
References
Publications (1)
- DERIVEDXia WX, Liang H, Lv X, Wang L, Ye YF, Ke LR, Xu LH, Guo X, Xiang YQ. Stage-specific concurrent chemoradiotherapy with or without induction chemotherapy for locoregionally advanced nasopharyngeal carcinoma: a retrospective, population-based study. Cancer Manag Res. 2019 Nov 20;11:9813-9827. doi: 10.2147/CMAR.S179139. eCollection 2019. PMID 31819619